Brief: Tango Therapeutics Announces First Patient Dosed In Tng462 Phase 1/2 Trial In Patients With Mtap-Deleted Solid Tumors
10/07/2023 12:33
Tango Therapeutics Inc TNGX.O :
* TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG462
PHASE
1/2 TRIAL IN PATIENTS WITH MTAP-DELETED SOLID TUMORS
Source text for Eikon: ID:nGNX3B1Vfb
Further company coverage: TNGX.O
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,